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thor. Tel.: þ1 913
zhong@kumc.eduAbstract CYP2D6 expression in liver is age-dependent. Because epigenetic mechanisms, such as
DNA methylation and histone modiﬁcations, modulate age-related gene expression during develop-
ment, and are highly conserved among species, the current study examined the epigenetic regulation of
age-related expression of the Cyp2d genes in mouse liver. DNA methylation (DNAme), histone 3
lysine 4 dimethylation (H3K4me2), and histone 3 lysine 27 trimethylation (H3K27me3) was
established by ChIP-on-chip tiling microarrays from mouse livers at prenatal, neonatal, and adult
stages. Levels of DNAme, H3K4me2, and H3K27me3 were analyzed in a genomic region containing
the Cyp2d clustering genes and their surrounding genes. Gradually increased expression levels of the
Cyp2d9, Cyp2d10, Cyp2d22, and Cyp2d26 genes from prenatal, through neonatal, to adult are
associated with gradually increased levels of H3K4me2 in the nucleosomes associated with these genes.
Gene expression patterns during liver development in several Cyp2d surrounding genes, such as
Srebf2, Sept3, Ndufa6, Tcf2, Nfam1, and Cyb5r3, could be also explained by changes of DNA
methylation, H3K4me2, or H3K27me3 in those genes. In conclusion, the current study demonstrates
that the changes of DNA methylation and histone modiﬁcations are associated with age-related
expression patterns of the Cyp2d genes and their surrounding genes in liver cells during development.
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Cytochrome P450 2D6 (CYP2D6) is an important drug
metabolizing enzyme, responsible for metabolizing 10–20%
of current prescribed drugs1. Signiﬁcant interindividual varia-
tion in CYP2D6-mediated drug metabolism exists in the
general population2,3. The varied phenotypes can be partially
explained by functional genetic polymorphisms in the CYP2D6
gene4–6. In addition to the genetic factors, age-dependent
developmental changes in CYP2D6 expression in human livers
are other important determinants of interindividual variability
in CYP2D6-mediated drug metabolism7,8. The developmental
changes in human liver CYP2D6 expression are not dependant
on genetic polymorphisms or environmental factors, but rely
on mechanisms controlling ontogenic expression of CYP2D6
in liver cells during development; however, the mechanisms
involved in regulating this event remains unclear.
Changes in gene expression caused by mechanisms other than
changes in the underlying DNA sequence are deﬁned as epige-
netics. It is desirable to examine whether epigenetic mechanisms
are involved in controlling the age-dependent developmental
changes of CYP2D6 expression in liver development. However,
there are several limitations for such studies using human liver
samples. First, variation in CYP2D6 expression in human livers at
various ages is controlled not only by age, but also by genetic
polymorphisms, environmental factors, drugs, and physiological
conditions. These factors are very difﬁcult to control when human
liver samples are used in a study. Second, moral, ethical and
technical limitations for studying human fetal and neonatal
samples have precluded an in-depth understanding of the epige-
netic mechanisms controlling CYP2D6 expression. Therefore, it
would be advantageous to have a laboratory animal model that
parallels the developmental patterns in humans where age, genetic
background, diet and environment could be controlled.Figure 1 Comparison of genomic organization between the mouse
500- and 300-regions. Based on the UCSC Genome Browser Mouse F
regions are located at mouse chromosome 15 from 81,964,524 to 83,00
Srebf2, sterol regulatory element binding factor 2; Sept3, neuronal-spec
Tcf20, transcription factor 20; Nfam1, nuclear factor of activated T-cel
3. Age-related gene expression of the Cyp2d genes and their surroundin
which are stored at GEO database with the accession
acc.cgi?acc=GSE13149). The patterns are deﬁned as: Pattern A for c
levels at any age; Pattern C for gradually increased levels from prenaIn this respect, mouse is an ideal model. First, many
epigenetic mechanisms are conserved between mice and
humans, and these epigenetic mechanisms have similar roles
in programming gene expression in mice and humans9,10.
Second, organization of the mouse Cyp2d gene cluster is similar
to the human CYP2D gene cluster (Fig. 1). The mouse Cyp2d
gene cluster contains eight Cyp2d coding and pseudo-genes,
including Cyp2d9, Cyp2d10, Cyp2d12, Cyp2d13, Cyp2d22,
Cyp2d26, Cyp2d34 and Cyp2d40 on mouse chromosome 15.
The comparable human CYP2D gene cluster contains one
coding gene, CYP2D6, and two pseudo-genes, CYP2D7P1 and
CYP2D8P1, on human chromosome 22. Both gene clusters are
in synteny with the same surrounding genes in the same order,
including Ndufa6, Sept3, and Srebf2 at the 50-region and Tcf20,
Nfam1, and Cyb5r3 at the 30-region. Third, the expression
patterns of some mouse Cyp2d genes, such as Cyp2d9,
Cyp2d10, Cyp2d22 and Cyp2d2611,12 are similar to human
CYP2D6 gene with gradually increased expression levels from
prenatal, through neonatal, to young adults8. Fourth, mice
have been used recently to study epigenetic regulation of
membrane transporters in different tissues13 and developmental
changes of Cyp3a gene expression in liver14.
DNA methylation and histone modiﬁcations are the two
most extensively studied epigenetic mechanisms involving in the
regulation of gene expression. DNA methylation is essential for
normal development15, and it regulates gene transcription either
by directly preventing the binding of transcription factors to
their DNA binding sites in gene promoters, or by indirectly
interfering in the recruitment of co-repressors by methyl-CpG
binding proteins16. Histone modiﬁcations are post-translational
modiﬁcations of histone N-terminal tails at various positions,
which can alter their interaction with DNA. The interactions
between DNA and modiﬁed histones can inﬂuence gene
transcription. More than 50 different types of histoneCyp2d cluster and the human CYP2D cluster and their adjacent
ebruary 2006 and human March 2006 Assemblies, two syntenic
9,974 and human chromosome 22 from 40,549,052 to 41,372,840.
iﬁc septin-3; Ndufa6, NADH dehydrogenase (ubiquinone) 1 alpha;
ls activation molecule 1; Cyb5r3, NADH-cytochrome b5 reductase
g genes was based on the microarray data generated by Li et al.11,
number GSE13149 (http://www.ncbi.nlm.nih.gov/geo/query/
onsistently low levels at any age; Pattern B for consistently high
tal, through neonatal, to adult.
Ye Li, Xiao-bo Zhong148modiﬁcations have been identiﬁed at various amino acid
residues with acetylation, methylation, phosphorylation, ubiqui-
tination, citrullination, sumoylation, or ADP-ribosylation.
Depending on which types of histone modiﬁcations are involved
and which amino acids are modiﬁed, some histone modiﬁca-
tions, such as acetylation of histone 3, di- or tri-methylation at
histone-3-lysine-4 (H3K4me2 or H3K4me3), and di-, or tri-
methylation at histone-3-lysine-36 (H3K36me2 or H3K36me3)
are associated with activation of gene transcription, but others,
such as di-or tri-methylation at histone-3-lysine-27 (H3K27me2
or H3K27me3) and di- or tri-methylation at histone-3-lysine-9
(H3K9me2 or H3K9me3) are associated with suppression of
gene transcription17–19. The current study selected three epige-
netic marks of DNA methylation, H3K4me2, and H3K27me3
to examine the roles of these epigenetic mechanisms in the
regulation of age-related gene expression of the Cyp2d and their
surrounding genes in mouse liver.2. Materials and methods
DNA methylation and histone modiﬁcations of H3K4me2 and
H3K27me3 in livers of C57BL/6 male mice at day2, 1, 5, and 45
were determined by ChIP-on-chip assays with the Affymetrix
GeneChip Mouse Tiling 2.0R E arrays (Affymetrix, Santa Clara,
CA) with detailed procedures previously described14. The raw
and processed data are stored in the Gene Expression Omnibus
(GEO) data base with the accession number, GSE14620
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14620).
The proﬁles of DNAme, H3K4me2, and H3K27me3 in a one MB
genomic region from Chr15:81,964,524 to Chr15:83,009,974 con-
taining the Cyp2d gene cluster and its surrounding genes were
extracted from the database. The original scanned ChIP-on-chip
data were further analyzed with Affymetrix tiling analysis software
(TAS) to generate binary analysis result (BAR) ﬁles that contain
the intensities of all probes on the arrays. The thresholds were set
as 4-fold signal increase of immunoprecipitated signals vs. non--
immunoprecipitated signals for H3K4me2 and H3K27me3, and
3-fold signal increases for DNA methylation, which corresponds
to an average false discovery rate of less than 0.02. A genomic
region with a sequence of4200 bp and an average signal increase
greater than the threshold was deﬁned as an enriched interval. A
genomic region with one or more enriched intervals in close
proximity to each other (at least one base overlap) at any given
age was deﬁned as an active region. The overall fold changes of
each epigenetic modiﬁcation in a gene were represented by average
peak values of all probes in the deﬁned active regions within gene
margins, which is arbitrarily deﬁned as 10,000 bps 500-from the
gene transcriptional start site to 10,000 bps after the 300–UTR end
of the gene.
To compare the epigenetic proﬁles from different cell types, the
proﬁles of H3K4me2 and H3K27me3 in the genomic region
(chr15: 81,964,524–83,009,974) in whole brain and embryonic
stem cells, deﬁned by ChIP-sequencing20, were downloaded from
the UCSC Genome Browser. Tissue-speciﬁc gene expression
proﬁles of the Cyp2d genes and their surrounding genes were
extracted from the BioGPS database (http://biogps.gnf.org) gen-
erated by Su et al.21.
In order to classify the epigenetic changes in the genomic
region (chr15: 81,964,524–83,009,974) in different tissues,
ontogenic epigenetic changes were deﬁned into four patterns.
In Pattern A, certain epigenetic modiﬁcation is not enriched atany age. In Pattern B, certain epigenetic modiﬁcation is
enriched at all ages. In Pattern C, certain epigenetic modiﬁca-
tion is gradually increased from prenatal, through neonatal, to
adult. In Pattern D, certain epigenetic modiﬁcation is gradu-
ally decreased from prenatal, through neonatal, to adult.
3. Results
3.1. Gene expression proﬁles
Relative mRNA levels of the Cyp2d genes and their 50-adjacent
genes of Srebf2, Sept3, and Ndufa6, as well as 30-adjacent genes of
Tcf20, Nfam1, and Cyb5r3 in mouse liver cells during develop-
ment were extracted from a published dataset11. Three patterns of
ontogenic gene expression were found (Fig. 1): in Pattern I,
Srebf2, Sept3, Tcf20, and Nfam1 are not expressed or expressed
at low levels at all ages; in Pattern II, Ndufa6 and Cyb5r3 are
consistently expressed at all ages; and in Pattern III, Cyp2d22,
Cyp2d9, Cyp2d10, and Cyp2d26 are expressed at gradually
increased levels from prenatal, through neonatal, to adult ages.
3.2. DNA methylation proﬁles
Signal enrichment of DNA methylation along the probes in
the 1 MB genomic region containing the Cyp2d cluster and
its adjacent regions is shown in Fig. 2A. Five enriched
intervals were identiﬁed (Table 1.1), corresponding to 2 active
regions, one in the Srebf2 gene and one in the upstream of the
Tcf20 gene (Table 2.1). Both of the active regions are
consistently high across all ages (Pattern B in Fig. 2B and
Table 3). No enrichment of DNA methylation were observed
within the Cyp2d genes at any ages, indicating DNA sequences
in this gene cluster were not hypermethylated at any age
during liver development (Fig. 2B and Table 3).
3.3. H3K4me2 proﬁles
Signal enrichment of H3K4me2 along the probes in the
1 MB genomic region containing the Cyp2d cluster and its
adjacent regions is shown in Fig. 3A. Various enriched
intervals of H3K4me2 were identiﬁed in this genomic region
in livers at prenatal day 2, neonatal day 1 and 5, and adult
day 45 (Table 1.2). A total of 29 active regions of H3K4me2
were found in this region (Table 2.2).
Table 3 lists the overall fold increases of H3K4me2 repre-
sented by average peak value of all probes in the deﬁned active
regions within margins of the associated genes. The data in
Table 3 and Fig. 3B show that with the various genes there are
four patterns of H3K4me2 during liver development.
H3K4me2, associated with the Sept3 and Nfam1 genes, is not
enriched at any age (Pattern A). For Ndufa6 and Cyb5r3 genes,
H3K4me2 is enriched at all ages (Pattern B). For Cyp2d22,
Cyp2d10, Cyp2d9, and Cyp2d26 genes, H3K4me2 gradually
increases from prenatal, through neonatal, to adult (Pattern
C). For Srebf2 and Tcf20 genes, H3K4me2 gradually decreases
from prenatal, through neonatal, to adult (Pattern D).
3.4. H3K27me3 proﬁles
Signal enrichment of H3K27me3 along the probes in the
1 MB genomic region containing the Cyp2d cluster and
Figure 2 DNA methylation along the Cyp2d cluster and its adjacent 500- and 300-regions during liver development. (A) Browser view of
fold changes of DNA methylation along the Cyp2d cluster and its adjacent 500- and 300-regions in livers of mice at different ages; (B) fold
enrichment of DNA methylation of the Cyp2d genes and the adjacent genes. The enrichment of DNA methylation is presented as the
average-fold changes over background of all probes in the deﬁned active regions within a gene. If no active regions are deﬁned within the
margins of a gene, the enrichment of DNA methylation is presented as the average fold changes over background of all probes within the
margins of the genes. Pattern A for consistently low levels at any age; Pattern B for consistently high levels at any age.
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enriched blocks (Block I and Block II) are observed and
consist of 13 enriched intervals, corresponding to 6 active
regions associated with the Srebf2, Sept3, and Nfam1 genes
(Tables 1.3, 2.3, and 3). In block I, 4 active regions of
H3K27me3 are associated with Srebf2 and Sept3, two of
which are found downstream of Sref2, whereas one is located
upstream of Sept3, and the last one is located in intron 1 of
Sept3. The enrichment of H3K27me3 within these genes
gradually decreases with age (Pattern D). In block II, the
enrichment of H3K27me3 is observed from the intergenic
region between Nfam1 and Cyb5r3, across the Nfam1 gene, to
downstream of Nfam1. The H3K27me3 enrichment in this
block is relatively consistent across all ages (Pattern B in
Table 3 and Fig. 4B). No H3K27me3 enrichment is observed
in the Cyp2d gene cluster (Table 3).3.5. H3K4me2 and H3K27me3 proﬁles in different types of
mouse cells
Table 4 summaries relative mRNA levels of the mouse Cyp2d
genes and their surrounding genes in liver, brain, and ES cells.
The Cyp2d genes are predominantly expressed in liver and notexpressed in brain and ES cells. Sept3 is mainly expressed in
brain, but not in liver and ES cells. Nfam1 is not expressed in
liver, brain, or ES cells. Other genes are expressed at various
levels in the three types of cells. Fig. 5 presents the epigenetic
proﬁles of H3K4me2 and H3K27me3 in whole brain and ES
cells downloaded from the UCSC Genome Browser database,
deﬁned by ChIP-sequencing20. In brain, Srebf2, Sept3,
Nadufa6, Cyp2d22, Tcf20, and Cyb5r3 are transcribed at
various levels, which are enriched for H3K4me2, but not
H3K27me3; whereas Cyp2d9, Cyp2d10, and Cyp2d26 are not
transcribed and have no enrichment of H3K4me2 and
H3K27me3. In ES cells, actively transcribed genes include
Sref2, Tcf20, and Cyb5r3, which are enriched with H3K4me2
alone, whereas, silent genes include Sept3, Ndufa6, Cyp2d22,
Cyp2d9, Cyp2d10, Cyp2d26, and Nfam1, which are either
enriched for both H3K4me2 and H3K27me3 together in the
promoters or not enriched for both H3K4me2 and H3K27me3.4. Discussion
The epigenetic proﬁles of DNA methylation and histone
modiﬁcations of H3K4me2 and H3K27me3 along the
1 MB genomic region (chr15: 81,964,524–83,009,974)



















1.1. Enriched intervals for DNA methylation
1 2 82,021,906 82,022,290 384 3.75 Srebf2 47,574 In gene
2 1 82,021,874 82,022,398 524 4.18 Srebf2 47,612 In gene
3 5 82,021,906 82,022,361 455 4.37 Srebf2 47,609 In gene
4 45 82,021,806 82,022,471 665 4.95 Srebf2 47,614 In gene
5 45 82,743,292 82,743,590 298 4.11 Tcf20 3541 Upstream
1.2. Enriched intervals for H3K4me2
1 2 81,972,923 81,973,469 546 5.38 Srebf2 1328 Upstream
2 2 81,975,667 81,976,444 777 5.46 Srebf2 1531 In gene
3 2 81,989,142 81,989,881 739 6.62 Srebf2 14,987 In gene
4 2 82,011,998 82,012,709 711 7.93 Srebf2 37,829 In gene
5 2 82,169,534 82,171,229 1695 7.76 Ndufa6 11,625 Downstream
6 2 82,171,970 82,173,304 1334 7.22 Ndufa6 9369 Downstream
7 2 82,174,329 82,176,026 1697 8.90 Ndufa6 6829 Downstream
8 2 82,178,995 82,180,127 1132 9.66 Ndufa6 2445 In gene
9 2 82,181,088 82,181,450 362 5.42 Ndufa6 737 In gene
10 2 82,182,839 82,183,148 309 11.79 Ndufa6 987 Upstream
11 2 82,724,809 82,725,144 335 5.02 Tcf20 14,924 In gene
12 2 82,725,429 82,726,370 941 5.53 Tcf20 14,001 In gene
13 2 82,992,127 82,992,415 288 5.14 Cyb5r3 7703 In gene
14 2 82,993,675 82,994,473 798 9.01 Cyb5r3 5900 In gene
15 2 82,995,437 82,997,255 1818 6.62 Cyb5r3 3628 In gene
16 2 82,998,735 82,999,568 833 11.96 Cyb5r3 823 In gene
17 1 81,972,923 81,973,399 476 5.34 Srebf2 1363 Upstream
18 1 81,975,811 81,976,444 633 4.64 Srebf2 1603 In gene
19 1 81,981,683 81,981,890 207 4.40 Srebf2 7262 In gene
20 1 81,988,764 81,989,881 1117 7.78 Srebf2 14,798 In gene
21 1 82,012,436 82,012,674 238 4.79 Srebf2 38,031 In gene
22 1 82,172,184 82,173,228 1044 7.07 Ndufa6 9300 Downstream
23 1 82,174,361 82,175,922 1561 7.82 Ndufa6 6865 Downstream
24 1 82,178,959 82,180,127 1168 9.80 Ndufa6 2463 In gene
25 1 82,181,088 82,181,412 324 5.39 Ndufa6 756 In gene
26 1 82,182,839 82,183,148 309 13.53 Ndufa6 987 Upstream
27 1 82,189,897 82,190,280 383 5.63 Ndufa6 8082 Upstream,
Cyp2d22 17,838 Downstream
28 1 82,234,161 82,234,586 425 5.45 Cyp2d10 572 In gene
29 1 82,724,845 82,725,144 299 4.78 Tcf20 14,906 In gene
30 1 82,725,875 82,726,370 495 5.38 Tcf20 13,778 In gene
31 1 82,973,353 82,973,575 222 4.50 Cyb5r3 26,510 Downstream
32 1 82,977,770 82,977,978 208 5.30 Cyb5r3 22,100 Downstream
33 1 82,993,675 82,994,336 661 6.63 Cyb5r3 5969 In gene
34 1 82,998,554 82,999,536 982 11.08 Cyb5r3 929 In gene
35 5 81,972,923 81,973,616 693 5.18 Srebf2 1255 Upstream
36 5 81,975,737 81,976,405 668 4.72 Srebf2 1547 In gene
37 5 81,989,104 81,989,881 777 5.67 Srebf2 14,968 In gene
38 5 82,012,071 82,012,709 638 5.92 Srebf2 37,866 In gene
39 5 82,172,080 82,173,228 1148 8.36 Ndufa6 9352 Downstream
40 5 82,174,361 82,175,958 1597 8.39 Ndufa6 6847 Downstream
41 5 82,178,995 82,180,127 1132 10.64 Ndufa6 2445 In gene
42 5 82,181,088 82,181,374 286 5.46 Ndufa6 775 In gene
43 5 82,182,839 82,183,148 309 12.43 Ndufa6 987 Upstream
44 5 82,189,790 82,190,280 490 6.98 Ndufa6 8029 Upstream
Cyp2d22 17,891 Downstream
45 5 82,191,902 82,192,188 286 4.67 Ndufa6 10,039 Upstream
Cyp2d22 15,881 Downstream
46 5 82,234,130 82,234,552 422 5.52 Cyp2d10 604 In gene
47 5 82,724,845 82,725,144 299 4.33 Tcf20 14,906 In gene
48 5 82,973,191 82,973,499 308 4.55 Cyb5r3 26,629 Downstream
49 5 82,992,127 82,992,415 288 5.15 Cyb5r3 7703 In gene
50 5 82,993,675 82,994,437 762 7.88 Cyb5r3 5918 In gene
51 5 82,998,519 82,999,568 1049 13.21 Cyb5r3 931 In gene
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52 45 81,975,811 81,976,405 594 4.61 Srebf2 1584 In gene
53 45 81,989,142 81,989,505 363 5.14 Srebf2 14,799 In gene
54 45 82,174,361 82,176,026 1665 8.70 Ndufa6 6813 Downstream
55 45 82,178,812 82,180,127 1315 8.14 Ndufa6 2537 In gene
56 45 82,181,088 82,181,374 286 4.77 Ndufa6 775 In gene
57 45 82,182,839 82,183,148 309 11.25 Ndufa6 987 Upstream
58 45 82,189,897 82,190,280 383 6.33 Ndufa6, 8082 Upstream
Cyp2d22 17,838 Downstream
59 45 82,203,217 82,204,532 1315 6.17 Cyp2d22 4052 In gene
60 45 82,205,252 82,206,216 964 6.00 Cyp2d22 2192 In gene
61 45 82,232,588 82,233,337 749 5.93 Cyp2d10 1983 In gene
62 45 82,233,777 82,234,765 988 9.29 Cyp2d10 674 In gene
63 45 82,275,979 82,276,405 426 5.36 Cyp2d9 3966 Upstream
64 45 82,281,486 82,282,602 1116 4.70 Cyp2d9 1886 In gene
65 45 82,619,576 82,619,937 361 4.48 Cyp2d26 2255 In gene
66 45 82,622,825 82,623,542 717 5.83 Cyp2d26 1172 Upstream
67 45 82,992,127 82,992,415 288 4.71 Cyb5r3 7703 In gene
68 45 82,993,675 82,994,336 661 5.56 Cyb5r3 5969 In gene
69 45 82,998,481 82,999,536 1055 10.51 Cyb5r3 966 In gene
1.3. Enriched intervals for H3K27me3
1 2 82,036,559 82,037,085 526 14.64 Srebf2 62,298 Downstream
2 2 82,041,855 82,043,912 2057 9.48 Srebf2 68,359 Downstream
3 2 82,101,129 82,102,323 1194 7.45 Sept3 931 Upstream
4 2 82,103,900 82,104,818 918 5.99 Sept3 1702 In gene
5 2 82,816,233 82,816,637 404 4.57 Nfam1 34,469 Downstream
6 1 82,036,559 82,036,845 286 8.94 Srebf2 62,178 Downstream
7 1 82,041,986 82,043,536 1550 5.41 Srebf2 68,237 Downstream
8 1 82,101,129 82,102,139 1010 6.78 Sept3 1023 Upstream
9 1 82,103,900 82,104,595 695 5.54 Sept3 1590 In gene
10 1 82,816,157 82,816,946 789 5.46 Nfam1 34,353 Downstream
11 1 82,817,777 82,818,119 342 4.11 Nfam1 32,956 Downstream
12 5 82,101,168 82,101,880 712 4.50 Sept3 1133 Upstream
13 5 82,104,178 82,104,420 242 4.26 Sept3 1642 In gene
Peak Val (Peak value): signal intensity at the peak of the interval.
Epigenetic regulation of developmental expression of Cyp2d genes in mouse liver 151containing the Cyp2d cluster and adjacent 500- and 300-regions
have been established in mice livers at various ages from
prenatal (day-2), neonatal (day 1 and day 5), to young adult
(day 45) using ChIP-on-chip tiling arrays. Fig. 6 illustrates the
patterns of the epigenetic proﬁles as well as gene expression as
deﬁned as: Pattern I for consistently low levels at any age;
Pattern II for consistently high levels at any age; Pattern III
for gradually increased levels from prenatal, through neonatal,
to adult; and Pattern IV for gradually decreased levels from
prenatal, through neonatal, to adult. The expression patterns
of the Cyp2d genes and their surrounding genes are associated
with the patterns of the epigenetic modiﬁcations in a gene-
speciﬁc manner.
As important xenobiotic metabolizing enzymes in liver, four
mouse Cyp2d members have a similar ontogenic expression
pattern (Gene Expression Pattern III: gradually increased
levels of gene expression across the developmental ages during
liver maturation). The levels of H3K4me2 also have a similar
pattern (H3K4me2 Pattern III) in the chromatin regions
associated with these genes. The enrichment of H3K4me2 is
widely distributed in the promoter around the TSS, in exons,
in introns, and in intergenic regions of these genes. Levels of
H3K27me3 and DNA methylation are consistently low in the
Cyp2d cluster region (H3K27me3 Pattern I). Therefore,gradual increase of H3K4me3 levels with age together with
consistently low levels of H3K27me3 and DNA methylation
may be the epigenetic mechanisms contributing to the gradual
increase of expression of these Cyp2d genes in mouse liver
during postnatal development.
Of the six genes in the 500- and 300-regions of the Cyp2d cluster,
Ndufa6 and Cyb5r3 are consistently expressed at any age during
postnatal liver development (Gene Expression Pattern II).
Naufa6 and Cyb5r3 are two enzymes ubiquitously expressed
in many tissues21. Naufa6 encodes NADH dehydrogenase
(ubiquinone) 1 alpha subcomplex 6, an accessory subunit of
the mitochondrial membrane respiratory chain complex I, which
is responsible for the transfer of electrons from NADH to the
respiratory chain22. Cyb5r3 encodes cytochrome b5 reductase 3,
which functions in the desaturation and elongation of fatty
acids, cholesterol biosynthesis, and drug metabolism in liver
cells23. As shown in Fig. 6, levels of H3K4me2 are consistently
high in the chromatin regions associated with the Ndufa6 and
Cyb5r3 genes in livers at any age (H3K4me2 Pattern II). The
enrichment of H3K4me2 is widely distributed in these two
genes, including upstream of the promoter, proximal promoter
around the TSS, and intergenic region of these genes. Levels of
both H3K27me3 and DNA methylation are consistently low
within these two genes (H3K27me3 Pattern I and DNAme












DNAme enrichment value Name of gene
associated
2 1 5 45
2.1. Active regions with DNA methylation enrichment
1 82,021,806 82,022,471 665 4 3.75 4.18 4.37 4.95 Srebf2
2 82,743,292 82,743,590 298 1 2.94 3.40 3.14 4.11 Tcf20
2.2. Active regions for H3K4me2
1 81,972,923 81,973,616 693 3 5.38 5.34 5.18 3.44 Srebf2
2 81,975,667 81,976,444 777 4 5.46 4.64 4.72 4.61 Srebf2
3 81,981,683 81,981,890 207 1 2.44 4.40 3.57 3.08 Srebf2
4 81,988,764 81,989,881 1117 4 6.62 7.78 5.67 5.14 Srebf2
5 82,011,998 82,012,709 711 3 7.93 4.79 5.92 2.76 Srebf2
6 82,169,534 82,171,229 1695 2 7.76 5.12 6.06 2.52 Ndufa6
7 82,171,970 82,173,304 1334 3 7.22 7.07 8.36 3.30 Ndufa6
8 82,174,329 82,176,026 1697 4 8.90 7.82 8.39 8.70 Ndufa6
9 82,178,812 82,180,127 1315 4 9.66 9.80 10.64 8.14 Ndufa6
10 82,181,088 82,181,450 362 4 5.42 5.39 5.46 4.77 Ndufa6
11 82,182,839 82,183,148 309 4 11.79 13.53 12.43 11.25 Ndufa6
12 82,189,790 82,190,280 490 3 4.69 5.63 6.98 6.33 Ndufa6,
Cyp2d22
13 82,191,902 82,192,188 286 1 3.91 3.71 4.67 3.23 Ndufa6,
Cyp2d22
14 82,203,217 82,204,532 1315 1 2.74 4.42 3.94 6.17 Cyp2d22
15 82,205,252 82,206,216 964 1 2.40 3.25 2.98 6.00 Cyp2d22
16 82,232,588 82,233,337 749 1 1.95 3.38 2.66 5.93 Cyp2d10
17 82,233,777 82,234,765 988 3 2.98 5.45 5.52 9.29 Cyp2d10
18 82,275,979 82,276,405 426 1 1.75 2.27 2.62 5.36 Cyp2d9
19 82,281,486 82,282,602 1116 1 1.34 2.29 2.43 4.70 Cyp2d9
20 82,619,576 82,619,937 361 1 1.88 2.52 2.86 4.48 Cyp2d26
21 82,622,825 82,623,542 717 1 2.11 2.99 3.26 5.83 Cyp2d26
22 82,724,809 82,725,144 335 3 5.02 4.78 4.33 3.38 Tcf20
23 82,725,429 82,726,370 941 2 5.54 5.38 4.70 3.95 Tcf20
24 82,973,191 82,973,575 384 2 3.95 4.50 4.55 3.86 Cyb5r3
25 82,977,770 82,977,978 208 1 4.88 5.30 4.42 4.28 Cyb5r3
26 82,992,127 82,992,415 288 3 5.14 3.44 5.16 4.71 Cyb5r3
27 82,993,675 82,994,473 798 4 9.01 6.63 7.88 5.56 Cyb5r3
28 82,995,437 82,997,255 1818 1 6.62 4.70 5.64 3.87 Cyb5r3
29 82,998,481 82,999,568 1087 4 11.96 11.08 13.21 10.51 Cyb5r3
2.3. Active regions for H3K27me3
1 82,036,559 82,037,085 526 2 14.64 8.94 6.82 2.88 Srebf2
2 82,041,855 82,043,912 2057 3 9.48 5.41 4.48 2.66 Srebf2
3 82,101,129 82,102,323 1194 3 7.45 6.78 4.50 3.15 Sept3
4 82,103,900 82,104,818 918 3 5.99 5.54 4.26 2.80 Sept3
5 82,816,157 82,816,946 789 2 4.58 5.46 3.98 3.96 Nfam1
6 82,817,777 82,818,119 342 1 3.16 4.11 3.37 2.65 Nfam1
Enrichment values are average enrichment of all probes in the active regions.
Ye Li, Xiao-bo Zhong152Pattern I). Consistently high levels of H3K4me3 together with
consistently low levels of H3K27me3 and DNA methylation
may be the epigenetic mechanisms contributing to the consistent
expression of the Ndufa6 and Cyb5r3 genes in mouse liver
during postnatal development.
The other four Cyp2d neighborhood genes of Sept3, Nfam1,
Srebf2, and Tcf20 are expressed at low levels in liver at all ages
during postnatal development (Gene Expression Pattern I), but
the epigenetic mechanisms for silencing their gene expression
appear to be different. Silencing Sept3 and Nfam1 expression
may be due to high levels of H3K27me3 within the chromatin
regions associated with these genes. Sept3 encodes septin 3,which is required for cytokinesis. Septin 3 is a neuron-speciﬁc
protein that is abundant in synaptic terminals24. Nfam1
encodes Nfat activating molecule with ITAM motif 1 and is
predominantly expressed in spleen B and T cells25. H3K27me3
enrichment is observed upstream of the TSS and the intergenic
regions of Sept3, as well as in the upstream and downstream of
Nfam1 at all ages. H3K27me3 enrichment of Nfam1 is
consistently high at all ages (H3K27me3 Pattern II), whereas,
H3K27me3 modiﬁcation of Sept3 gradually decreases from
prenatal, through neonatal, to adult (H3K27me3 Pattern IV).
However, because H3K27me3 modiﬁcation is not essential for
the transmission between active and repressive chromatin
Table 3 Epigenetic modiﬁcations during mouse liver development in the 1 MB genomic region containing the Cyp2d cluster and adjacent 50- and 30-regions.
Chromation region
50-Region of Cyp2d cluster Cyp2d cluster 30-Region of Cyp2d cluster
Gene Srebf2 Sept3 Ndufa6 Cyp2d22 Cyp2d10 Cyp2d9 Cyp2d26 Tcf20 Nfam1 Cyb5r3
Pattern of gene expression in liver A A B C C C C A A B
DNAme
No. interval 4 0 0 0 0 0 0 1 0 0
No. active region 1 0 0 0 0 0 0 1 0 0
Position of active region In gene 50-
Average peak value
Day-2 3.75 1.42 1.35 1.51 1.22 1.16 1.35 2.94 1.50 1.54
Day 1 4.18 1.39 1.37 1.50 1.27 1.12 1.27 3.40 1.50 1.47
Day 5 4.37 1.29 1.22 1.44 1.15 1.31 1.29 3.14 1.31 1.47
Day 45 4.95 1.52 1.29 1.49 1.08 1.12 1.05 4.11 1.77 1.28
Change pattern B A A A A A A B A A
H3K4me2
No. interval 15 0 20 6 4 2 2 5 0 15
No. active region 5 0 8 2 2 2 2 2 0 6
Position of active region 50- and in gene 50-, in gene, and 30- In gene and 30- In gene 50- and in gene 50- and in gene In gene In gene and 30-
Average peak value
Day 2 5.57 1.56 7.42 3.43 2.46 1.54 2.00 5.28 1.84 6.93
Day 1 5.39 1.63 7.26 4.25 4.41 2.28 2.76 5.08 2.21 5.94
Day 5 5.01 1.56 7.87 4.64 4.09 2.52 3.06 4.51 2.16 6.81
Day 45 3.81 1.92 6.03 5.43 7.61 5.03 5.16 3.67 1.69 5.47
Change pattern D A B C C C C D A B
H3K27me3
No. interval 4 6 0 0 0 0 0 0 3 0
No. active region 2 2 0 0 0 0 0 0 2 0
Position of active region 30- 50-, in gene In gene, 30-
Average peak value
Day 2 12.06 6.72 1.12 1.33 1.68 1.73 1.47 1.70 3.87 1.22
Day 1 7.18 6.16 1.13 1.20 1.49 1.58 1.47 1.41 4.78 1.24
Day 5 5.65 4.38 1.17 1.12 1.34 1.36 1.38 1.33 3.67 1.22
Day 45 2.77 2.97 1.04 1.02 1.04 1.00 1.07 1.12 3.30 1.13
Change pattern D D A A A A A A B A
The presented data are the average peak values of all probes in the deﬁned active regions of the genes.
Change pattern:
Pattern A: consistently low levels across all ages.
Pattern B: consistently high levels across all ages.
Pattern C: gradually increased levels from prenatal, through neonatal, to adult.













































Figure 3 H3K4me2 modiﬁcation along the Cyp2d cluster and its adjacent 500- and 300-regions during liver development. (A) Browser view
of fold changes of H3K4me2 along the Cyp2d cluster and its adjacent 500- and 300-regions in livers of mice at different ages; (B) fold
enrichment of H3K4me2 in Cyp2d and adjacent genes. Enrichment of H3K4me2 is presented as the average fold changes over
background of all probes in the deﬁned active regions within a gene. If no active regions are deﬁned within the margins of a gene, the
enrichment of H3K4me2 is presented as the average-fold changes over background of all probes within the margins of the genes. Pattern
A for consistently low levels at any age; Pattern B for consistently high levels at any age; Pattern C for gradually increased levels from
prenatal, through neonatal, to adult; Pattern D for gradually decreased levels from prenatal, through neonatal, to adult.
Ye Li, Xiao-bo Zhong154states, the transcription of Sept3 is still suppressed in adult
livers without the appearance of active epigenetic modiﬁca-
tions, such as H3K4me2 in its promoter.
Srebf2 encodes sterol regulatory element binding transcription
factor 2, which is an important transcriptional activator in the
regulation of the LDL receptor and cholesterol synthesis, as well
as the fatty acid synthesis pathway to a lesser extent26. Srebf2 is
essential for normal development, but overexpression of Srebf2
in livers of mice can cause marked increases of cholesterol and
triglycerides in liver27 and lipotoxicity in the pancreas28. In
addition, single nucleotide polymorphisms in human SREBP-2
gene are associated with a higher risk of early onset myocardial
infarction29 and hypercholesterolaemic syndrome30. Thus, the
presence of Srebf2 in hepatic nuclei is tightly controlled by
multiple steps and sensitive to the depletion of cholesterol as well
as endoplasmic reticulum stress31,32. H3K4me2, H3K27me3, and
DNA methylation enrichment are all observed within the gene
margin of Srebf2 during the developmental ages examined in this
study. H3K4me2 enrichment is widely distributed in the promo-
ter and intergenic region of Srebf2, however, the levels of
H3K4me2 enrichment gradually decrease from prenatal to adult
ages (H3K4me2 Pattern IV). The gradual decrease ofH3K27me3 is also observed downstream of the Srebf2 gene
from prenatal to adult stages (H3K27me3 Pattern IV). Mean-
while, a gradual increase of DNA methylation is observed in the
Srebf2 gene region. Thus, the control of Srebf2 transcription in
liver cells may be due to a balance of H3K4me2 and H3K27me3,
as well as DNA methylation in the chromatin associated with
Srebf2. Tcf20 encodes transcription factor 20, which is a DNA
binding transactivation factor and coactivator of other transcrip-
tion factors33. The upregulation of TCF20 transcription have
been observed in human tumors, such as small-cell lung cancer,
advanced adenocarcinomas34, and desmoid tumors35. In the
present study, DNA methylation enrichment is observed in the
proximal promoter of Tcf20 with consistently high levels at all
ages (DNAme Pattern II). Enrichment of H3K4me2 is observed
in an intronic region of Tcf20, and H3K4me2 gradually
decreases from prenatal to adult age (H3K4me2 Pattern IV).
Thus, the suppression of Tcf20 during liver development may be
associated with DNA methylation across all ages.
Vast evidence has demonstrated that mammalian genomes
use various epigenetic mechanisms to regulate gene silencing and
expression during development. Some studies demonstrate that
the interactions between histone modiﬁcations and DNA
Figure 4 H3K27me3 modiﬁcation along the Cyp2d cluster and its adjacent 50- and 30-regions during liver development. (A) browser view
of fold changes of H3K27me3 along the Cyp2d cluster and its adjacent 50- and 30-regions in livers of mice at different ages; (B) fold
enrichment of H3K27me3 in Cyp2d and adjacent genes. Enrichment of H3K27me3 is presented as the average fold changes over
background of all probes in the deﬁned active regions within a gene. If no active regions are deﬁned within the margins of a gene, the
enrichment of H3K27me3 is presented as the average fold changes over background of all probes within the margins of the genes. Pattern
A for consistently low levels at any age; Pattern B for consistently high levels at any age; Pattern C for gradually increased levels from
prenatal, through neonatal, to adult; Pattern D for gradually decreased levels from prenatal, through neonatal, to adult.
Table 4 Gene expression patterns in mouse liver, whole






Srebf2  þ þ
Sept3 ND þþþ 
Ndufa6 þ þ 
Cyp2d22 þþþ  ND
Cyp2d9 þþþ ND ND
Cyp2d10 þþþ ND ND
Cyp2d26 þþþ ND ND
Tcf20 þ þ þþ
Nfam1 ND ND 
Cyb5r3 þþ þþ þ
aGene expression (X) in a certain tissue is compared to the
mean level of its expression in 61 mouse tissues, then represents
as follows: ‘‘ND’’ not detectable; ‘‘’’ less than mean; ‘‘þ’’
meanoXo3mean; ‘‘þþ’’ 3meanoXo100mean;
‘‘þþþ’’ X4100mean. The data were extracted from the
BioGPS database (http://biogps.gnf.org) generated by Su
et al.21.
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genes during development36–38, whereas other studies show that
the changes in chromatin states by the switch between active and
repressive epigenetic marks achieves the activation or suppres-
sion of gene expression at speciﬁc developmental stages14,39,40.
To further provide evidence to support epigenetic regula-
tion of developmental changes in mouse liver Cyp2d expres-
sion, the epigenetic proﬁles of H3K4me2 and H3K27me3 in
adult liver with brain and embryonic stem cells were compared
(Fig. 5). Brain and embryonic stem cells have different gene
expression patterns of Cyp2d and their surrounding genes
(Table 2). The tissue speciﬁc gene expression patterns can also
be explained by epigenetic changes associated with the genes in
different types of cells.
In conclusion, the present study demonstrates that changes
in epigenetic modiﬁcations of H3K4me2, H3K27me3, and
DNA methylation may explain the developmental changes in
expression of mouse liver Cyp2d genes and their surrounding
genes on chromosome 15. For Cyp2d cluster, H3K4me2,
which is associated with actively transcribed genes, showed a
changing pattern during liver maturation. This epigenetic
modiﬁcation may regulate the onset of transcriptional activa-
tion of the Cyp2d genes at different ages. In comparison,
H3K27me3 and DNA methylation, which are associated with
gene silencing, showed little change in Cyp2d cluster. For
Figure 5 Browser views of enrichment of H3K4me2 and H3K27me3 along the Cyp2d cluster in mouse whole brain isolated from 4 to 6
weeks old male 129SvJae/C57BL/6 mice and mouse embryonic stem cells. Data are obtained from Mikkelsen et al.20.
Figure 6 Patterns of dynamic changes of H3K4me2, H3K27me3, and DNA methylation along the Cyp2d cluster and its adjacent 500- and
300-regions during liver development. Bars indicate genes with different epigenetic modiﬁcation patterns. A small black or white circle
represents one-fold enrichment of H3K4me2 or H3K27me3 in active regions at the associated positions, respectively. A black star
represents one-fold enrichment of DNA methylation in active regions at the associated positions. Pattern A for consistently low levels at
any age; Pattern B for consistently high levels at any age; Pattern C for gradually increased levels from prenatal, through neonatal, to
adult; Pattern D for gradually decreased levels from prenatal, through neonatal, to adult.
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Epigenetic regulation of developmental expression of Cyp2d genes in mouse liver 157adjacent 50- and 30-regions of Cyp2d cluster, H3K4me2,
H3K27me3 and DNA methylation demonstrate the changes
or cooperative feature during liver maturation, in consistence
to their expression patterns too. Our ﬁndings provide the basis
for further experimental conﬁrmation of the epigenetic
mechanisms in age-related Cyp2d gene expression.
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